Latest articles

EU PERSPECTIVES - The latest hantavirus outbreak is forcing Europe to confront an uncomfortable reality: vaccines or treatments against some dangerous viruses may never reach the market. Not because the science is impossible, but because developing them is not commercially attractive for pharmaceutical companies. Brussels is increasingly...

EURACTIV - Benoît van den Hove tells Euractiv that scaling biotech companies at a global level still depends on capital that Europe does not yet mobilise at sufficient scale. Read more

APM MARKET ACCESS - The European Council and the European Parliament have reached a provisional agreement on implementing tariff elements of the EU-U.S. Joint Statement, as pharmaceutical industry groups warn that continued uncertainty around transatlantic trade could disrupt drug supply chains and increase pressure on smaller innovative companies....

EURACTIV - Healthcare is increasingly being asked to square a difficult circle: deliver care without contributing to the environmental pressures driving disease in the first place. At the same time, systems are being pushed to shift from treatment to prevention as the basis for long-term sustainability. Read more